Drug Combination Details
| General Information of the Combination (ID: C39948) | |||||
|---|---|---|---|---|---|
| Name | Ampelopsin NP Info | + | Erlotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CYBB | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1650 | CVCL_1483 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway. Lung Cancer. 2017 Apr;106:115-124. | |||
